Sunaxer and HepaVue get FIT support
Summary
FIT is pleased to announce that two new companies have been awarded loans to support their innovations: Sunaxer, for its receiver technology to collect solar heat for industrial processes, and HepaVue for its virtual biopsy to detect liver disease in a painless, affordable, safe and accessible way. In recent years, industrial solar heat has seen strong growth and is seen as a cost-effective substitute for fossil fuels, even in moderate climates such as Germany and Switzerland. All at an extremely competitive price thanks to this innovative, patented approach where low-cost sol-gel coating replaces expensive vacuum processes, and where energy-efficient induction heating is also used in the manufacture of Sunaxer absorbers. The CHF 100,000 Tech Seed loan from FIT will enable Sunaxer to cover the salary of an operator and acquire a welding unit, which is essential if its products are to comply with current standards. The CHF 100,000 Tech Seed loan granted by FIT will enable HepaVue to finalise its artificial intelligence software and begin production of its radiotracers.